{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:29:04Z","timestamp":1777577344811,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.MAZUMS. Rec.1396.3074"],"award-info":[{"award-number":["IR.MAZUMS. Rec.1396.3074"]}],"id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"crossref","award":["IR.TUMS.IKHC.Rec.1399.075"],"award-info":[{"award-number":["IR.TUMS.IKHC.Rec.1399.075"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Iranian children were vaccinated with the scheduled two doses of monovalent measles vaccine (mMV) from 1984. In December 2003, a nationwide campaign of measles-rubella (MR) immunization was established to vaccinate 5\u201325\u2009year- old individuals. In 2004, the mMV was replaced with measles- mumps- rubella (MMR) vaccine. Despite the high vaccination coverage, the outbreaks of measles still occur in the country. In this Study, the MR immunity status of various age groups, vaccinated with different schedules was investigated, and the immunologic response of seronegative subjects to revaccination was examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study was conducted among 7\u201333-year-old healthy individuals with a documented history of measles vaccination from November 2017 to June 2018. The subjects were categorized as follows: group A, including 20\u201333\u2009year-old individuals; vaccinated with 1\u20132 doses of mMV at ages 9 and 15\u2009months, and revaccinated with MR, group B, including 15\u201319-year-old individuals, vaccinated with two doses of mMV at 9 and 15\u2009months of age, and received additional dose of MMR upon school entrance, group C, including 11\u201314\u2009year-old individuals, vaccinated with two-doses of MMR at the ages of 15\u2009months and 6\u2009years, and group D, including 7\u201310\u2009year-old individuals vaccinated with two-doses of MMR vaccine at the ages 12 and 18\u2009months, respectively. Levels of antimeasles- antirubella IgG antibodies in the collected sera were measured. Also antimeasles- antirubella IgM and IgG of seronegative individuals were reexamined at 4\u20136\u2009weeks after MMR revaccination. The collected data were analyzed using descriptive statistical methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 635 individuals were investigated in this study. Group A, 98; group B, 295; group C, 139; and group D, 103 persons. Overall, 12.3 and 18.4% of the population were seronegative for measles and rubella antibodies. This rate varied greatly between the 4 groups: group A, 0\/0\u20132%; group B,15.2\u201325.0%; group C,11.5\u201317.2%; and groupD,14.6\u201318.4%. After revaccination, 92 and 94.9% of seronegative individuals showed IgG response to measles and rubella vaccines, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the high coverage rate of M-R containing vaccines, a significant number of vaccinated subjects were seronegative for measles and rubella, possibly because of secondary vaccine failure; this may negatively affect measles-rubella elimination targets in the country. If these findings are confirmed in similar future studies, a more robust regional\/national supplementary immunization activity will be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-05970-7","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T17:02:54Z","timestamp":1616691774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran"],"prefix":"10.1186","volume":"21","author":[{"given":"Hana","family":"Saffar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Khalifeloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-6262","authenticated-orcid":false,"given":"Mohammad-Jafar","family":"Saffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad-Reza","family":"Parsaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholam-Reza","family":"Ghorbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samaneh","family":"Salarvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Aarabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"5970_CR1","first-page":"205","volume":"92","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Measles vaccine: WHO position paper. WKLY Epidemiol Rec No 17. 2017;92:205\u201328.","journal-title":"WKLY Epidemiol Rec No 17"},{"key":"5970_CR2","unstructured":"World Health Organization. Measle. Key factsheet: 5 2019. www.WHO.int\/news-room\/fact-sheet\/detailmeasles."},{"issue":"Suppl 1","key":"5970_CR3","first-page":"S116","volume":"189","author":"SC Redd","year":"2004","unstructured":"Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, et al. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis. 2004;189(Suppl 1):S116\u201322.","journal-title":"J Infect Dis"},{"issue":"7","key":"5970_CR4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/cid\/cix510","volume":"65","author":"SC Perez","year":"2017","unstructured":"Perez SC, De Serres G, Bureau A, Skowronski DM. Reduced antibody response to infant measles vaccination: effects based on type and timing of the first vaccine dose persist after the second dose. Clin Infeci Dis. 2017;65(7):1094\u2013102. https:\/\/doi.org\/10.1093\/cid\/cix510.","journal-title":"Clin Infeci Dis"},{"issue":"Suppl 1","key":"5970_CR5","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1093\/infdis\/jir102","volume":"204","author":"A Uzicanin","year":"2011","unstructured":"Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis. 2011;204(Suppl 1):S133\u201348. https:\/\/doi.org\/10.1093\/infdis\/jir102.","journal-title":"J Infect Dis"},{"issue":"3","key":"5970_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00430-016-0451-4","volume":"205","author":"H Holzmann","year":"2016","unstructured":"Holzmann H, Hengel H, Tenbusch M, Doerr HW. Eradication of measles: remaining challenges. Med Microbiol Immunol. 2016;205(3):201\u20138. https:\/\/doi.org\/10.1007\/s00430-016-0451-4.","journal-title":"Med Microbiol Immunol"},{"key":"5970_CR7","unstructured":"Center for Disease Control and Prevention (CDC). Global Measles Outbreaks. 2019.\u00a0www.cdc.gov\/globalhealth\/measles\/global measlesoutbreaks.html."},{"issue":"1","key":"5970_CR8","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.15167\/2421-4248\/jpmh2018.59.1.853","volume":"59","author":"MA Palamara","year":"2018","unstructured":"Palamara MA, Visalli G, Picerno I, DI Pietro A, Puglisi G, et al. Measles outbreak from February to august 2017 in Messina, Italy. J Prev Med Hyg. 2018;59(1):E8\u2013E13. https:\/\/doi.org\/10.15167\/2421-4248\/jpmh2018.59.1.853.","journal-title":"J Prev Med Hyg"},{"issue":"6","key":"5970_CR9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/infdis\/jis923","volume":"207","author":"G De Serres","year":"2013","unstructured":"De Serres G, Markowski F, Toth E, Landry M, Auger D, Mercier M, et al. Largest measles epidemic in North America in a decade--Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events. J Infect Dis. 2013;207(6):990\u20138. https:\/\/doi.org\/10.1093\/infdis\/jis923.","journal-title":"J Infect Dis"},{"issue":"7","key":"5970_CR10","first-page":"196","volume":"64","author":"J Zipprich","year":"2015","unstructured":"Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K. Measles outbreak--California, December 2014-February 2015. MMWR Morb Mortal Wkly Rep. 2015;64(7):196.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"38","key":"5970_CR11","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.15585\/mmwr.mm6438a7","volume":"64","author":"L Breakwell","year":"2015","unstructured":"Breakwell L, Moturi E, Helgenberger L, Gopalani SV, Hales C, Lam E, et al. Measles outbreak associated with vaccine failure in adults--Federated States of Micronesia, February-august 2014. MMWR Morb Mortal Wkly Rep. 2015;64(38):1088\u201392. https:\/\/doi.org\/10.15585\/mmwr.mm6438a7.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"5970_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.17795\/jhealthscope-10353","volume":"2","author":"J Nejati","year":"2013","unstructured":"Nejati J, Sargolzaie N, Kiani M, Mahjoob M, Hashemi A. Measles epidemiology in sistan and baluchistan province during April 2006-march 2011. Health Scope. 2013;2(1):58\u201362. https:\/\/doi.org\/10.17795\/jhealthscope-10353.","journal-title":"Health Scope"},{"issue":"1","key":"5970_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.7883\/yoken.65.45","volume":"65","author":"S Izadi","year":"2012","unstructured":"Izadi S, Zahraie SM, Sartipi M. An investigation into a measles outbreak in Southeast Iran. Jpn J Infect Dis. 2012;65(1):45\u201351.","journal-title":"Jpn J Infect Dis"},{"issue":"3","key":"5970_CR14","first-page":"375","volume":"43","author":"M Moghadam","year":"2014","unstructured":"Moghadam M, Afsarkazerooni P, Ebrahimi M, Soltani M, Razmpoor A, Pirasteh E, et al. Measles outbreak in south of Iran, where vaccine coverage was high: a case-series study. Iran J Public Health. 2014;43(3):375\u201380.","journal-title":"Iran J Public Health"},{"issue":"3","key":"5970_CR15","volume":"17","author":"M Karami","year":"2017","unstructured":"Karami M, Zahraei SM, Sabouri A, Soltanshahi R, Biderafsh A, Piri N, et al. Documentation of measles elimination in Iran: evidences from 2012 to 2014. J Res Health Sci. 2017;17(3):e00387.","journal-title":"J Res Health Sci"},{"issue":"1","key":"5970_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12889-019-7060-2","volume":"19","author":"N Piri","year":"2019","unstructured":"Piri N, Karami M, Tapak L, Zahraei M, Mohammadi Y. Monitoring Progress towards the elimination of measles in Iran: supporting evidence from 2014 to 2016 by application of measles outbreaks data. BMC Public Health. 2019;19(1):687. https:\/\/doi.org\/10.1186\/s12889-019-7060-2.","journal-title":"BMC Public Health"},{"issue":"9984","key":"5970_CR17","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/S0140-6736(14)60539-0","volume":"385","author":"N Lambert","year":"2015","unstructured":"Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA, Lambert N, et al. Rubella. Lancet. 2015;385(9984):2297\u2013307. https:\/\/doi.org\/10.1016\/S0140-6736(14)60539-0.","journal-title":"Lancet"},{"issue":"1","key":"5970_CR18","first-page":"Abstract","volume":"1","author":"A Manteghi","year":"1972","unstructured":"Manteghi A. Changes in the epidemiology of measles due to mass-vaccination in Iran (1961-1971). Iran J Public Health. 1972;1(1):Abstract https:\/\/ijph.tums.ac.ir\/index.php\/ijph\/article\/view\/1516.","journal-title":"Iran J Public Health"},{"issue":"5","key":"5970_CR19","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.60725","volume":"11","author":"A Shafyi","year":"2018","unstructured":"Shafyi A, Mohammadi A. Measles vaccines in Iran: a 50-year review of vaccine development, production and effectiveness (1967-2017). Jundishapur J Microbiol. 2018;11(5):e60725.","journal-title":"Jundishapur J Microbiol"},{"issue":"3","key":"5970_CR20","first-page":"1","volume":"11","author":"MJ Saffar","year":"2001","unstructured":"Saffar MJ, Ajami A, Pourfatemi F. An immunological study in the pregnant women infected with rubella virus in mazandaran province in 1999-2000. Nameh Daneshgah (J). Mazandaran Univ Med Sci. 2001;11(3):1\u20136 (In Persian).","journal-title":"Mazandaran Univ Med Sci"},{"issue":"3","key":"5970_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.22074\/ijfs.2019.5562","volume":"13","author":"M Azami","year":"2019","unstructured":"Azami M, Jaafari Z, Soleymani A, Badfar GH, Abbasalizadeh SH. Rubella immunity in pregnant Iranian women: a systematic review and meta-analysis. Int J Fertil Steril. 2019;13(3):169\u201377. https:\/\/doi.org\/10.22074\/ijfs.2019.5562.","journal-title":"Int J Fertil Steril"},{"issue":"1","key":"5970_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2334-5-44","volume":"5","author":"J Sadighi","year":"2005","unstructured":"Sadighi J, Eftekhar H, Mohammad K. Congenital rubella syndrome in Iran. BMC Infect Dis. 2005;5(1):44. https:\/\/doi.org\/10.1186\/1471-2334-5-44.","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"5970_CR23","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1093\/infdis\/jir076","volume":"204","author":"SM Zahraei","year":"2011","unstructured":"Zahraei SM, Gouya MM, Azad TM, Soltanshahi R, Sabouri A, et al. Successful control and impending elimination of measles in the Islamic Republic of Iran. J Infect Dis. 2011;204(Suppl 1):S305\u201311. https:\/\/doi.org\/10.1093\/infdis\/jir076.","journal-title":"J Infect Dis"},{"issue":"1","key":"5970_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijid.2007.03.013","volume":"12","author":"B Pourabbas","year":"2008","unstructured":"Pourabbas B, Ziyaeyan M, Alborzi A, Mardaneh J. Efficacy of measles and rubella vaccination one year after the nationwide campaign in shiraz, Iran. Int J Infect Dis. 2008;12(1):43\u20136. https:\/\/doi.org\/10.1016\/j.ijid.2007.03.013.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"5970_CR25","doi-asserted-by":"publisher","first-page":"516","DOI":"10.26719\/2009.15.3.516","volume":"15","author":"Z Yekta","year":"2009","unstructured":"Yekta Z, Pourali R, Taravati MR, Shahabi S, Salary S, Khalily F, et al. Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran. East Mediterr Health J. 2009;15(3):516\u201325. https:\/\/doi.org\/10.26719\/2009.15.3.516.","journal-title":"East Mediterr Health J"},{"issue":"1","key":"5970_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055043","volume":"8","author":"B Honarvar","year":"2013","unstructured":"Honarvar B, Moghadami M, Moattari A, Emami A, Odoomi N, Bagheri Lankarani K. Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in shiraz, southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign. PLoS One. 2013;8(1):e55043. https:\/\/doi.org\/10.1371\/journal.pone.0055043.","journal-title":"PLoS One"},{"issue":"3","key":"5970_CR27","first-page":"244","volume":"15","author":"M Keshavarz","year":"2016","unstructured":"Keshavarz M, Nicknam MH, Tebyanian M, Shahkarami MK, Izad M. Anti-rubella, mumps and measles IgG antibodies in medical students of Tehran University. Iran J Allergy Asthma Immunol. 2016;15(3):244\u201350.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"6","key":"5970_CR28","first-page":"1412","volume":"14","author":"S Izadi","year":"2018","unstructured":"Izadi S, Zahraei S, Mokhtari-Azad T. Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. HumVacc Immunother. 2018;14(6):1412\u20136.","journal-title":"HumVacc Immunother"},{"issue":"1","key":"5970_CR29","doi-asserted-by":"publisher","DOI":"10.34172\/jrhs.2020.05","volume":"20","author":"M Karami","year":"2020","unstructured":"Karami M, Khazaei S, Zahraei SM, Mokhtari Azad T, Zahiri A, Moradi AR, et al. Measles outbreak in a rural population in Bahar District, Hamadan Province, west of Iran in 2018. J Res Healt Sci. 2020;20(1):e00470. https:\/\/doi.org\/10.34172\/jrhs.2020.05.","journal-title":"J Res Healt Sci"},{"issue":"23","key":"5970_CR30","first-page":"511","volume":"63","author":"N Teleb","year":"2014","unstructured":"Teleb N, Lebo E, Ahmed H, Hossam AR, El Sayed T, et al. Progress toward measles elimination--eastern Mediterranean region, 2008-2012. MMWR Morb Mortal Wkly Rep. 2014;63(23):511\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"5970_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.26719\/2019.25.10.667","volume":"25","author":"N Teleb","year":"2019","unstructured":"Teleb N, Atta H, Hajjeh R. Measles and rubella elimination in the eastern Mediterranean region: successes and challenges. East Mediterr Health J. 2019;25(10):667\u20138. https:\/\/doi.org\/10.26719\/2019.25.10.667.","journal-title":"East Mediterr Health J"},{"issue":"4","key":"5970_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094846","volume":"9","author":"V Salimi","year":"2014","unstructured":"Salimi V, Abbasi S, Zahraei SM, Fatemi-Nasab G, Adjaminezhad-Fard F, Shadab A, et al. Implementation of a national measles elimination program in Iran: phylogenetic analysis of measles virus strains isolated during 2010-2012 outbreaks. PLoS One. 2014;9(4):e94846. https:\/\/doi.org\/10.1371\/journal.pone.0094846.","journal-title":"PLoS One"},{"issue":"1","key":"5970_CR33","first-page":"1","volume":"27","author":"AR Emami Naeini","year":"2002","unstructured":"Emami Naeini AR, Davarpanah MA, Sherkat R, Karimi I, Hashemi J. Should we consider another booster dose of measles vaccine? Ir J Med Sci. 2002;27(1):1\u20133.","journal-title":"Ir J Med Sci"},{"issue":"1","key":"5970_CR34","volume":"9","author":"Z Yekta","year":"2007","unstructured":"Yekta Z, Porali R, Taravati MR, Salary S, Khalily F, et al. Measles IgG sero-prevalence and its attributable factors in 5\u201325-year-old cases prior mass vaccination campaign in Urmia, northeastern Iran. Iran Red Crescent Med J. 2007;9(1):e95867.","journal-title":"Iran Red Crescent Med J"},{"issue":"5","key":"5970_CR35","first-page":"573","volume":"12","author":"MJ Saffar","year":"2006","unstructured":"Saffar MJ, Alraza-Amiri M, Ajami A, Baba-Mahmoodi F, Khalilian AR, et al. Measles seroepidemiology among adolescents and young adults: response to revaccination. East Mediterr Health J. 2006;12(5):573\u201381.","journal-title":"East Mediterr Health J"},{"issue":"1","key":"5970_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3923\/tmr.2006.39.48","volume":"1","author":"A Zamani","year":"2006","unstructured":"Zamani A, Daneshjou K. Seroepidemiology of measles in primary school students in Tehran, Iran. Trends Med Res. 2006;1(1):39\u201348.","journal-title":"Trends Med Res"},{"issue":"2","key":"5970_CR37","first-page":"77","volume":"28","author":"V Salimi","year":"2006","unstructured":"Salimi V, Mokhtari-Azad T, Gooya MM, Hamkar R, Esteghamati AR, et al. Seroepidemiology of measles in 5-25-year-old age group before measles\/rubella mass vaccination campaign in Tabriz (2003). Med J Tabriz Unive Med Sci. 2006;28(2):77\u201382 (In Persian).","journal-title":"Med J Tabriz Unive Med Sci"},{"issue":"2","key":"5970_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.vaccine.2019.10.026","volume":"38","author":"SM Zahraei","year":"2020","unstructured":"Zahraei SM, Mokhtari-Azad T, Izadi S, Mohammadi M, Sabouri A. Seroprevalence of anti-rubella and anti-measles antibodies in women at the verge of marriage in Iran. Vaccine. 2020;38(2):235\u201341. https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.026.","journal-title":"Vaccine."},{"issue":"1","key":"5970_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12879-020-4870-x","volume":"20","author":"S Carazo","year":"2020","unstructured":"Carazo S, Billard MN, Boutin A, Serres GD. Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):251. https:\/\/doi.org\/10.1186\/s12879-020-4870-x.","journal-title":"BMC Infect Dis"},{"issue":"4\u20135","key":"5970_CR40","doi-asserted-by":"crossref","first-page":"468","DOI":"10.26719\/2004.10.4-5.468","volume":"10","author":"A Karimi","year":"2004","unstructured":"Karimi A, Arjomandi A, Alborzi A, Rasouli M, Kadivar MR, Obood B, et al. Prevalence of measles antibody in children of different ages in shiraz, Islamic Republic of Iran. East Mediterr Health J. 2004;10(4\u20135):468\u201373.","journal-title":"East Mediterr Health J"},{"issue":"14","key":"5970_CR41","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1016\/j.vaccine.2005.12.015","volume":"24","author":"JR Kremer","year":"2006","unstructured":"Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccinees--a longitudinal study. Vaccine. 2006;24(14):2594\u2013601. https:\/\/doi.org\/10.1016\/j.vaccine.2005.12.015.","journal-title":"Vaccine."},{"issue":"10","key":"5970_CR42","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/infdis\/jis568","volume":"206","author":"M Kontio","year":"2012","unstructured":"Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis. 2012;206(10):1542\u20138. https:\/\/doi.org\/10.1093\/infdis\/jis568.","journal-title":"J Infect Dis"},{"issue":"1","key":"5970_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170257","volume":"12","author":"J Smetana","year":"2017","unstructured":"Smetana J, Chlibek R, Hanovcova I, Sosovickova R, Smetanova L, Gal P, et al. Decreasing Seroprevalence of measles antibodies after vaccination - possible gap in measles protection in adults in the Czech Republic. PLoS One. 2017;12(1):e0170257. https:\/\/doi.org\/10.1371\/journal.pone.0170257.","journal-title":"PLoS One"},{"issue":"33","key":"5970_CR44","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1016\/j.vaccine.2017.06.058","volume":"35","author":"HJ Kang","year":"2017","unstructured":"Kang HJ, Han YW, Kim SJ, Kim YJ, Kim AR, Kim JA, et al. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine. 2017;35(33):4126\u201332. https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.058.","journal-title":"Vaccine."},{"issue":"52","key":"5970_CR45","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1016\/j.vaccine.2008.09.012","volume":"26","author":"I Velicko","year":"2008","unstructured":"Velicko I, M\u00fcller LL, Pebody R, Gergonne B, Aidyralieva C, Kostiuchenko N, et al. Nationwide measles epidemic in Ukraine: the effect of low vaccine effectiveness. Vaccine. 2008;26(52):6980\u20135. https:\/\/doi.org\/10.1016\/j.vaccine.2008.09.012.","journal-title":"Vaccine."},{"issue":"17","key":"5970_CR46","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.vaccine.2008.02.028","volume":"26","author":"AV Atrasheuskaya","year":"2008","unstructured":"Atrasheuskaya AV, Kulak MV, Neverov AA, Rubin S, Ignatyev GM. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005. Vaccine. 2008;26(17):2111\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2008.02.028.","journal-title":"Vaccine."},{"issue":"1","key":"5970_CR47","first-page":"12","volume":"1","author":"H Saffar","year":"2013","unstructured":"Saffar H, Saffar MJ, Saffar H. Vaccination in developing countries: a review of probable factors for lower responses to vaccine. J Pediatr Rev. 2013;1(1):12\u20138.","journal-title":"J Pediatr Rev"},{"issue":"7","key":"5970_CR48","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s10096-009-0702-z","volume":"28","author":"MJ Saffar","year":"2009","unstructured":"Saffar MJ, Ajami A, Khalilian AR, Saffar H. The impact of maternal measles-rubella immunization on the 12-month-old infant's immune response to measles-mumps-rubella vaccine immunogenicity. Eur J Clin Microbiol Infect Dis. 2009;28(7):845\u20137. https:\/\/doi.org\/10.1007\/s10096-009-0702-z.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"5970_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/tropej\/fmq102","volume":"57","author":"MJ Saffar","year":"2011","unstructured":"Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, et al. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes. J Trop Pediatr. 2011;57(5):347\u201351. https:\/\/doi.org\/10.1093\/tropej\/fmq102.","journal-title":"J Trop Pediatr"},{"issue":"4","key":"5970_CR50","doi-asserted-by":"publisher","first-page":"578","DOI":"10.5812\/jjm.4563","volume":"5","author":"A Shamsizadeh","year":"2012","unstructured":"Shamsizadeh A, Nikfar R, Makvandi M, Hakimzadeh M. Alisamir, et al. Seroprevalence of measles, mumps and rubella antibodies in 18 months and 6.5 years old children: 6 months after measles-mumps-rubella (MMR) vaccination. Jundishapur J Microbiol. 2012;5(4):578\u201381. https:\/\/doi.org\/10.5812\/jjm.4563.","journal-title":"Jundishapur J Microbiol"},{"issue":"1","key":"5970_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.13161\/AIM.0012","volume":"16","author":"S Rafiei Tabatabaei","year":"2013","unstructured":"Rafiei Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, Abdinia B, et al. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children. Arch Iran Med. 2013;16(1):38\u201341. https:\/\/doi.org\/10.13161\/AIM.0012.","journal-title":"Arch Iran Med"},{"issue":"12","key":"5970_CR52","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1080\/21645515.2016.1214346","volume":"12","author":"SM Zahraei","year":"2016","unstructured":"Zahraei SM, Izadi S, Mokhtari-Azad T. Factors affecting the seroconversion rate of 12-month-old babies after the first injection of measles vaccine in the southeast of Iran. Hum Vaccin Immunother. 2016;12(12):3118\u201324. https:\/\/doi.org\/10.1080\/21645515.2016.1214346.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"5970_CR53","doi-asserted-by":"publisher","first-page":"396","DOI":"10.26719\/2015.21.6.396","volume":"21","author":"S Izadi","year":"2015","unstructured":"Izadi S, Mokhtari-Azad T, Zahraei SM. Measles vaccination coverage and seroprevalence of anti-measles antibody in south-East Islamic Republic of Iran. East Mediterr Health J. 2015;21(6):396\u2013402. https:\/\/doi.org\/10.26719\/2015.21.6.396.","journal-title":"East Mediterr Health J"},{"issue":"5","key":"5970_CR54","doi-asserted-by":"publisher","first-page":"e1126","DOI":"10.1542\/peds.2012-3975","volume":"132","author":"F Defay","year":"2013","unstructured":"Defay F, De Serres G, Skowronski DM, Boulianne N, Ouakki M, et al. Measles in children vaccinated with 2 doses of MMR. Pediatrics. 2013;132(5):e1126\u201333. https:\/\/doi.org\/10.1542\/peds.2012-3975.","journal-title":"Pediatrics."},{"issue":"9","key":"5970_CR55","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/cid\/ciy286","volume":"67","author":"JD Cherry","year":"2018","unstructured":"Cherry JD, Zahn M. Clinical characteristics of measles in previously vaccinated and unvaccinated patients in California. Clin Infect Dis. 2018;67(9):1315\u20139. https:\/\/doi.org\/10.1093\/cid\/ciy286.","journal-title":"Clin Infect Dis"},{"issue":"30","key":"5970_CR56","doi-asserted-by":"publisher","first-page":"1800373","DOI":"10.2807\/1560-7917.ES.2018.23.30.1800373","volume":"23","author":"A Bernadou","year":"2018","unstructured":"Bernadou A, Astrugue C, M\u00e9chain M, Le Galliard V, Verdun-Esquer C, et al. Measles outbreak linked to insufficient vaccination coverage in nouvelle-Aquitaine region, France, October 2017 to July 2018. Euro Surveill. 2018;23(30):1800373.","journal-title":"Euro Surveill"},{"issue":"3","key":"5970_CR57","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/cid\/cis439","volume":"55","author":"G De Serres","year":"2012","unstructured":"De Serres G, Boulianne N, Defay F, Brousseau N, Beno\u00eet M, et al. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. Clin Infect Dis. 2012;55(3):394\u2013402. https:\/\/doi.org\/10.1093\/cid\/cis439.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05970-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05970-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05970-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T08:18:15Z","timestamp":1671697095000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05970-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5970"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05970-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-40094\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-40094\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-40094\/v3","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was provided ethical approval by the Mazandaran No: IR. MAZUMS. Rec.1396.3074 and Tehran IR. TUMS.IKHC. Rec.1399.075. The study obtained the consent of all participants and they signed and were informed of consent form prior to the investigation. Consent was also obtained from a parent or guardian on behalf of any participant under the age of 16. All participants were assured about confidentially and that their contribution would be on a voluntary basis as well as that they had full rights to withdraw from the study at any time.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"305"}}